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SCFCyclin F-dependent degradation of CDC6
suppresses DNA re-replication
David Walter1, Saskia Hoffmann1, Eirini-Stavroula Komseli2, Juri Rappsilber3,4, Vassilis Gorgoulis2,5 & Claus
Storgaard Sørensen1
Maintenance of genome stability requires that DNA is replicated precisely once per cell cycle.
This is believed to be achieved by limiting replication origin licensing and thereby restricting
the ﬁring of each replication origin to once per cell cycle. CDC6 is essential for eukaryotic
replication origin licensing, however, it is poorly understood how CDC6 activity is constrained
in higher eukaryotes. Here we report that the SCFCyclin F ubiquitin ligase complex prevents
DNA re-replication by targeting CDC6 for proteasomal degradation late in the cell cycle. We
show that CDC6 and Cyclin F interact through deﬁned sequence motifs that promote CDC6
ubiquitylation and degradation. Absence of Cyclin F or expression of a stable mutant of CDC6
promotes re-replication and genome instability in cells lacking the CDT1 inhibitor Geminin.
Together, our work reveals a novel SCFCyclin F-mediated mechanism required for precise once
per cell cycle replication.
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T
o ensure that chromosomal DNA is precisely duplicated
and no sections of DNA are re-replicated, eukaryotic
replication origins must ﬁre no more than once in a single
cell cycle1–4. To limit ﬁring of origins to once per cell cycle, the
two steps of replication initiation—origin licensing and origin
ﬁring—are temporally separated: ﬁrst, CDC6 and CDT1
collaborate from late mitosis to late G1 phase to load
complexes of the minichromosome maintenance 2–7 proteins
at replication origins to form pre-replicative complexes
(pre-RCs)5–7. Second, two types of protein kinases, cell division
cycle 7 (CDC7) and the S phase cyclin-dependent kinases (CDKs)
convert pre-RCs into bidirectional replisomes at each origin
during S phase8–10. To avoid re-replication, it is crucially
important to suppress licensing of newly replicated DNA until
cells are in late phases of mitosis. Mechanisms that prevent
re-licensing of replicated DNA include the degradation of the
licensing protein CDT1 (refs 1,2) as well as inhibition of CDT1
by Geminin11–14. Inhibition of CDC6, however, is poorly
understood. CDC6 is phosphorylated by CDKs during S-phase
and CDK-dependent phosphorylation of CDC6 beyond G1 can
trigger nuclear export of exogenous CDC6 (refs 15–17). However,
endogenous CDC6 is predominantly nuclear throughout the cell
cycle18–20 and only a small fraction of endogenous CDC6 is
exported from the nucleus18–20. Thus, mechanisms underlying
control of CDC6 function beyond G1 phase are still elusive. Here
we show that CDC6 is targeted for proteasomal degradation late
in the cell cycle by the SCFCyclin F ubiquitin ligase complex. We
show that CDC6 and Cyclin F interact through deﬁned sequence
motifs that promote CDC6 ubiquitylation and degradation.
Absence of Cyclin F or expression of a stable mutant of CDC6
promotes re-replication and genome instability in cells lacking
the CDT1 inhibitor Geminin. Together, our work reveals a novel
SCFCyclin F-mediated mechanism required for precise once per
cell cycle replication.
Results
CDC6 and cyclin F interact through deﬁned molecular motifs.
It is not well understood how CDC6 activity is suppressed in cell
cycle stages beyond G1 phase, which are the phases where re-
replication is an obvious threat to genome integrity. We hypo-
thesized that the SCFCyclin F ubiquitin ligase could be central in
regulating CDC6 activity because we uncovered a very marked
interaction between Cyclin F and CDC6 in a mass spectrometry
screen for Cyclin F interactors (Supplementary Fig. 1a). Cyclin F
is the founding member of the family of F-box proteins, which are
evolutionarily conserved substrate recognition subunits of
SCF(Skp1-Cul1-F-box protein) ubiquitin ligase complexes and
mediate the proteolysis of eukaryotic proteins21,22. Cyclin F was
previously shown to regulate deoxyribonucleotide triphosphate
production, centrosome duplication and spindle formation
through targeted degradation of SCFCyclin F substrates, that is,
NUSAP1, RRM2 and CP110 (refs 23–25). Furthermore, we
recently uncovered a novel role for Cyclin F in suppression of
B-Myb through direct protein interaction26. As expected from the
known function of Cyclin F, the mass spectrometry analysis also
revealed the presence of many peptides corresponding to the
SCFCyclin F subunits Skp1 and Cul1 (Supplementary Fig. 1a).
To conﬁrm the association between CDC6 and Cyclin F, we
immunoprecipitated endogenous Cyclin F and detected an
interaction with endogenous CDC6 (Fig. 1a). This interaction
occurs predominantly during late cell cycle stages, that is, G2 and
M phase as shown by co-immunoprecipitation analysis of
endogenous Cyclin F in synchronized U2OS cells (Fig. 1b).
Because both Cyclin F and CDC6 localize predominantly but not
exclusively to the nucleus15,25, we asked where the two proteins
could interact. Cells stably expressing V5-tagged CDC6 were
co-stained with antibodies to Cyclin F and V5 tag. Both Cyclin
F- and V5-tagged CDC6 were nuclear during G2 phase of the cell
cycle (Supplementary Fig. 1a). These results together with the
co-immunoprecipitation experiments suggest that Cyclin F and
CDC6 interact in the nucleus.
We next investigated the interaction between Cyclin F and
CDC6. Cyclin F has a Cyclin box domain, which contains a
hydrophobic patch motif22,25. In Cyclin F, this hydrophobic
patch with the amino-acid sequence MRYIL (Met-Arg-Tyr-
Ile-Leu) associates with the cyclin-binding motif (Cy motif)
Arginine-X-Leucine in its substrates24,25. We asked whether the
interaction between Cyclin F and CDC6 is dependent on the
Cyclin box domain in Cyclin F and found that Cyclin F
containing a mutation in the hydrophobic patch (MR/AA) failed
to co-immunoprecipitate endogenous CDC6 (Fig. 1c). Notably,
co-immunoprecipitation analysis of mutant Cyclin F MR/AA
revealed binding with the SCF(Cyclin F) subunit Cul1
(Supplementary Fig. 1d), suggesting that overall integrity of
mutant Cyclin F MR/AA is not impaired. Further, we investigated
whether the interaction between Cyclin F and CDC6 depends on
the conserved Cy motif in CDC6. CDC6 contains a Cy motif
between amino acids 93 and 100 (ref. 15). Deletion of amino acids
93–100 (dl 93–100) containing the Cy-motif abolishes the
interaction between CDC6 and Cyclin F (Fig. 1d) but not
between CDC6 and its known interaction partner CDH1
(refs 27,28; Supplementary Fig. 1c), suggesting that the complex
formation between Cyclin F and CDC6 depends on the Cy-motif
in CDC6 and that the integrity of CDC6 dl93–100 is not
impaired. Next, we analysed whether Cyclin F and CDC6 are
interacting directly and if so, whether the Cy-motif in CDC6 and
the Cyclin box domain in Cyclin F are required for this
interaction. We co-incubated puriﬁed recombinant WT and dl
93–100 mutant glutathione S-transferase (GST)-tagged CDC6
N-terminal fragments (GST-CDC6 1–362 WT and GST-CDC6
1–362 dl93–100), respectively, with either in vitro translated
35S-labelled WT or MR/AA mutant Cyclin F (Fig. 1e). We found
that the WT but not MR/AA mutant Cyclin F interacts with
GST-CDC6 1–362 WT (Fig. 1e). Further, we found that this
interaction depends on amino acids 93 to 100 in CDC6 (Fig. 1e).
Together, these data suggest that CDC6 directly interacts with
Cyclin F via the Cy-motif in CDC6 and the Cyclin box domain in
Cyclin F.
CDC6 is targeted for degradation by SCFCyclin F. To test
whether Cyclin F could regulate protein stability of CDC6
through proteasomal degradation, we analysed CDC6 protein
levels throughout the cell cycle in the presence and absence of
Cyclin F. Endogenous CDC6 is unstable and it accumulated after
treatment of cells with the proteasomal inhibitor MG132 during S
(t¼ 3), G2 (t¼ 10) and mitosis (Fig. 2a). Importantly, Cyclin F
depletion led to accumulation of CDC6 in G2 and M phase but
had little impact on CDC6 levels in S phase (Fig. 2a). This
indicates that proteasomal degradation of CDC6 in G2/M phase
cells is dependent on Cyclin F. Consistently, depletion of Cyclin F
in U2OS cells with several different short interfering RNAs
(siRNAs) led to increased CDC6 protein levels during mitosis
(Supplementary Fig. 2a). To conﬁrm that CDC6 is regulated by
proteasomal degradation in a Cyclin F-dependent manner, we
analysed CDC6 protein levels during mitosis in the presence of
cycloheximide (CHX). CHX allows analysis of protein turnover
by blocking new protein synthesis through translation inhibition.
Indeed, we found that both depleting Cyclin F as well as inhi-
biting the proteasome with MG132 caused stabilization of CDC6
during mitosis after CHX addition (Fig. 2b). Consistent with the
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role of SCF-mediated control of CDC6, treatment of cells with the
SCF complex E3 ligase inhibitor MLN4924 caused stabilization of
CDC6, which was marked after CHX addition during mitosis
(Supplementary Fig. 2b). The anaphase-promoting complex
(APC) targets CDC6 for degradation during G1 phase28,
but has no impact on CDC6 stability in mitosis as evidenced by
stability measurement upon CDH1 depletion, the substrate
adaptor protein of APC (Supplementary Fig. 2c). Notably,
immunoprecipitated wild-type (WT) Cyclin F, but not F-box
mutant Cyclin F(LP/AA)25, promoted the in vitro ubiquitylation
of co-immunoprecipated CDC6 (Fig. 2c). Together, these results
suggest that Cyclin F mediates the degradation of CDC6 during
G2 and M phase of the cell cycle by forming an active SCF
ubiquitin ligase complex.
The amino terminus of CDC6 contains three CDK
phosphorylation sites, that is, serine residues S54, S74 and S106
(ref. 15). These phosphorylation sites appear to be the
major functional CDK sites in CDC6, as mutation of these
abolishes phosphorylation of CDC6 in vivo and in vitro15,17.
Phosphorylation of yeast Cdc6p by S and M phase CDKs targets
Cdc6p for SCF-dependent ubiquitylation and subsequent
degradation29. In contrast, human CDC6 phosphorylated by
CDKs is prone to nuclear export15–17 and was shown to be
protected from APC-dependent ubiquitylation and subsequent
degradation27. To investigate whether CDK-mediated phospho-
rylation of CDC6 regulates Cyclin F-mediated degradation of
CDC6, we asked whether protein stability of CDC6 during
mitosis is modulated by CDK phosphorylation. We analysed
protein stability of mutant CDC6 where the three known CDK-
phosphorylated serine residues S54, S74 and S106 were replaced
with either alanine (AAA) to mimic the unphosphorylated state
or aspartic acid (DDD) to mimic the phosphorylated state.
Protein stability of AAA or DDD CDC6 was not altered after
CHX addition during mitosis when compared with WT CDC6
(Fig. 3a). In contrast, the dl 93–100 mutant was more stable than
the WT CDC6 protein after CHX addition (Fig. 3a). Similarly, dl
93–100 CDC6 stably expressed in human TIG-3 ﬁbroblasts was
markedly increased during mitosis when compared with WT,
AAA and DDD CDC6 (Supplementary Fig. 3a). Notably, the
increased stability of dl93–100 mutant CDC6 was not caused by a
lack of APC-dependent degradation of CDC6, as the stability of
CDC6 mutated in the APC recognition motifs RKRL and KEN at
residues 56–59 and 81–83 (mutated to ‘AKRA’ and ‘AAA’,
respectively) was comparable to WT CDC6 during mitosis
(Supplementary Fig. 3b). Notably, WT and dl93–100 mutant
CDC6 exhibited indistinguishable cellular localization throughout
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Figure 1 | CDC6 and Cyclin F interact through deﬁned molecular motifs. (a) Whole-cell extracts of U2OS cells were generated, lysates were
immunoprecipitated (IP) with anti-Cyclin F antibody and IPs were analysed by immunoblotting as indicated. (b) U2OS cells were synchronized at G1/S by
using a double-thymidine block before release into fresh medium. Whole-cell extracts were generated at the indicated time points, lysates were IP with
anti-Cyclin F antibody and IPs were analysed by immunoblotting as indicated. (c) HEK-293T cells were transfected with an empty vector, FLAG-tagged
wild-type Cyclin F (WT) or FLAG-tagged mutant Cyclin F(MR/AA). Whole-cell extracts were IP with anti-FLAG resin, and IPs were analysed by
immunoblotting as indicated. *Notes a cross reacting band in the CDC6 immunoblot. (d) HEK-293Tcells were transfected with an empty vector, HA-tagged
wild-type CDC6 (WT) or HA-tagged mutant CDC6 (dl 93–100). Whole-cell extracts were IP with anti-HA resin, and IPs were analysed by immunoblotting
as indicated. (e) The interaction between recombinant WT and dl 93–100 mutant GST-CDC6 fragments (amino acids 1–362) and in-vitro translated and
S35-methionine-labelled WTand MR/AA mutant Cyclin F was tested. GSTalone was used as a negative control. The GST-fusion proteins were precipitated
by glutathione-agarose afﬁnity chromatography and the interaction with the in vitro translated S35-labelled proteins was visualized by autoradiography.
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the cell cycle (Supplementary Fig. 3c), suggesting that the change
in protein stability is not a consequence of different localization of
WT and dl93–100 mutant CDC6, respectively. Furthermore,
reduction of Cyclin F by siRNA stabilized WT CDC6 but had no
effect on the already stabilized dl 93–100 mutant (Fig. 3b).
Finally, Cyclin F could be detected in haemagglutinin (HA)
immunoprecipitates with either WT, AAA or DDD HA-CDC6
but not with dl 93–100 HA-CDC6 (Fig. 3c). Thus, WT, as well as
AAA and DDD mutant CDC6, are regulated by SCFCyclin F,
but the dl 93–100 mutant is resistant to Cyclin F-mediated
degradation because of its inability to interact with Cyclin F.
Cyclin F suppresses genome instability. Licensing of DNA
replication origins by the assembly of pre-RCs is tightly regulated
and requires the combined action of CDC6 and CDT1 (refs 5–7).
Reduction of CDT1 activity by proteasomal degradation or by the
CDT1 inhibitor Geminin have been described as mechanisms
preventing re-replication by re-licensing of replicated DNA
during late cell cycle stages11,12. We analysed whether Cyclin
F-mediated degradation of CDC6 is preventing re-replication and
analysed the DNA content in cells treated with siRNA targeting
Cyclin F. Here, we observed limited re-replication and
accumulation of cells with DNA content greater than 4N in
Cyclin F-depleted cells (Fig. 4a and Supplementary Fig. 4a,c).
These results are consistent with data obtained in several systems,
in which the overexpression of CDC6 is not sufﬁcient to induce
re-replication15,28,30,31. Furthermore, the data are consistent with
the notion that CDC6 and CDT1 cooperate in licensing and that
several overlapping mechanisms exist to prevent re-replication3.
We therefore hypothesized that the degradation of CDC6 by
Cyclin F cooperates with mechanisms that suppress CDT1
activity. Indeed, depletion of both Cyclin F and the CDT1
inhibitor Geminin caused substantial re-replication as manifested
by a proportion of cells with DNA content greater than 4N
(Fig. 4a and Supplementary Fig. 4a,c). We further analysed
DNA re-replication at intermediate times after siRNA-induced
depletion of Cyclin F and/or Geminin (Supplementary Fig. 4b,c)
and consistently found substantially more cells with DNA
content 44N in cells co-depleted for Cyclin F and Geminin as
CDC6
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Figure 2 | CDC6 is targeted for ubiquitylation and degradation by SCFCyclin F. (a) U2OS cells were synchronized at G1/S by using a double-thymidine
block. Transfection of siRNAs was performed in the ﬁrst thymidine block as indicated. Cells were released and treated with MG132 for 90min as indicated
and whole-cell extracts were analysed by immunoblotting as indicated. Nocodazole was added for 3 h as indicated to prevent cells from entering the
next G1 phase. Quantiﬁcation of immunoblots of CDC6 is indicated. Individual lanes were quantiﬁed using ImageJ software and normalized to Actin loading
control. For each time-point, the protein level of CDC6 transfected with control siRNA (siCtrl) in the absence of MG132 was arbitrary set to 1. Error bars
represent s.d. (n¼ 3). (b) U2OS cells were transfected with control (siCtrl) or Cyclin F (siCycl F) siRNA. After 48 h, cells were treated with nocodazole for
an additional 5 h and the protein stability in cells obtained by mitotic shake-off was assessed by CHX and MG132 treatment for 90min and immunoblotting
as indicated. Protein stability of CDC6 was assessed and relative CDC6 abundance was determined by densitometry and normalized to actin with the
amount of CDC6 in the ﬁrst and fourth line, respectively, arbitrarily set to 1. Error bars represent s.d. (n¼ 3). (c) HEK-293T cells were transfected with an
empty vector, HA-tagged wild-type Cyclin F (WT), or HA-tagged mutant Cyclin F(LP/AA). Whole-cell extracts were immunoprecipitated (IP) with anti-HA
resin and used in a ubiquitylation assay.
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compared with Geminin depletion alone (Supplementary Fig. 4c),
suggesting that Cyclin F is important for suppressing
re-replication when CDT1 activity is high. Re-replication leads
to genomic instability as evidenced by the formation of
DNA double-strand breaks (DSBs), and these DNA lesions
activate ataxia-telangiectasia mutated checkpoint pathways32.
We therefore measured DNA DSB formation and ataxia-
telangiectasia mutated-dependent DNA damage checkpoint
activation in siRNA-treated cells. Depletion of Cyclin F or
Geminin alone did not lead to marked DNA DSBs and DNA
damage checkpoint activation (Fig. 4b and Supplementary
Fig. 4d). However, combined depletion of both Cyclin F and
Geminin lead to marked formation of DSBs and the activation of
DNA damage checkpoints (Fig. 4b,c and Supplementary Fig. 4d).
These data further highlight that Geminin and Cyclin F cooperate
in maintaining genome integrity, through joint suppression of the
major licensing factors CDC6 and CDT1. Notably, siRNA
depletion of Geminin in cells expressing the dl93–100 mutant,
but not WT CDC6, caused a marked activation of DNA
damage checkpoint signalling and re-replication (Fig. 4d and
Supplementary Fig. 5a). In comparison to previous reports11,13,14,
we observed rather limited re-replication in Geminin-depleted
cells. We hypothesized that the underlying reason for the
observed difference may be a consequence of our experimental
setup of the co-depletion experiment, where cells are ﬁrst
depleted with Cyclin F and control siRNA, respectively, and
24 h later with Geminin and control siRNA, respectively. To test
whether this is indeed the case, we depleted Geminin in U2OS
cells stably expressing V5-tagged LacZ, WT CDC6 or the stable
dl93–100 mutant CDC6, respectively. Under these conditions,
we found that Geminin depletion in cells expressing LacZ and
WT CDC6 leads to re-replication similar to previous studies
when Geminin was depleted in U2OS cells11,14 (Supplementary
Fig. 5b). However, Geminin depletion in cells expressing the
stable dl93–100 mutant CDC6 caused a dramatic increase in
re-replication as compared with Geminin depletion in cells
expressing LacZ and WT CDC6, respectively (Supplementary
Fig. 5b). Together, these data suggest that Cyclin F prevents
re-replication and genome instability by targeting CDC6 for
degradation. We further analysed the biological signiﬁcance of the
checkpoint response in the absence of Cyclin F as observed in
Fig. 4b–d. Cellular senescence is a tumorigenesis barrier imposed
by DNA damage checkpoints33,34 and we therefore speculated
that the absence of Cyclin F in cells with aberrant CDT1 activity
would lead to cellular senescence. Indeed, we observed induction
of cellular senescence in TIG-3 human ﬁbroblasts depleted for
Cyclin F and Geminin as evidenced by senescence-associated
b-galactosidase activity (Fig. 4e).
Cyclin F suppresses DNA re-replication during G2 phase. Next,
we hypothesized that Cyclin F-mediated degradation of CDC6 is
critical to limit licensing speciﬁcally during late cell cycle stages,
that is, G2 and M phase, when Cyclin F associates with and
targets CDC6 for degradation (Figs 1b and 2a,b). Notably, we
found that cells co-depleted for Cyclin F and Geminin completed
an apparently normal S phase (Fig. 5a and Supplementary
Fig. 6a,b) and exhibited no obvious signs of DNA replication
stress and DNA damage such as phosphorylation of CHK1 at
S317 and RPA at S4/S8 (Supplementary Fig. 6b,c), but underwent
cell cycle delay at the G2-M boundary (Fig. 5a). Similarly, siRNA
depletion of Geminin in cells expressing dl93–100 mutant but not
WT CDC6 imposed a cell cycle delay at the G2-M boundary
(Supplementary Fig. 5c). Notably, cells with DNA content 44N
started to appear after completing an apparently normal S phase
in the absence of Cyclin F and Geminin 15 h after a G1/S release
(Supplementary Fig. 6a). We therefore reasoned that inhibition of
CDC6 by Cyclin F prevents licensing and re-replication during
G2 and early M phase and that the observed cell cycle arrest
in cells co-depleted for Cyclin F and Geminin is caused by
re-replication in G2 cells. To test whether replication in cells
co-depleted for Cyclin F and Geminin is indeed occurring during
G2 phase of the cell cycle, we analysed aberrant DNA replication
during late cell cycle stages. Cells were pulse labelled with the
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thymidine analogue 5-ethynyl-2’-deoxyuridine (EdU) for 45min
immediately before cell ﬁxation, and late G2 and mitotic cells
were analysed for EdU incorporation by co-staining cells for
phosphorylated histone H3 at serine 10 (H3S10p), a marker for
late G2 and M phase. Most control-, Cyclin F- and Geminin-
depleted H3S10p-positive cells were EdU negative (Fig. 5b), as
expected to be the case in cells where DNA replication was
completed before the EdU pulse, that is, at least 45min before the
onset of H3S10 phosphorylation in late G2. However, a sub-
stantial amount of cells co-depleted for Cyclin F and Geminin
that were positive for H3S10 phosphorylation were also repli-
cating as evidenced by positive EdU incorporation (Fig. 5b).
Thus, our data suggest that Cyclin F and Geminin suppress re-
replication during G2 phase, a cell cycle stage where available
CDK and CDC7 kinase activities can support ﬁring of inappro-
priately licensed origins.
Discussion
To ensure replication happens once and only once during the cell
cycle, the two steps of replication initiation, origin licensing and
ﬁring, are temporarily separated. If inappropriate re-licensing of
replication origins occurs from S phase to mitosis, origins may
ﬁre more than once within a single cell cycle, which can result in
re-replication of DNA. Several overlapping mechanisms prevent
re-licensing1,2,11–14, however, the regulation of the key licensing
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protein CDC6 was so far poorly understood in this process. The
results presented here reveal that the E3-ligase SCFCyclin F
restrains CDC6 activity to suppress re-replication. Cyclin F
accumulates in late stages of the cell cycle24,25, and our data
uncover a pronounced interaction with CDC6 at this
stage mediated via a speciﬁc Cyclin-binding motif. This
promotes SCFCyclin F-dependent degradation of CDC6 thereby
safeguarding chromosomal DNA by securing that no sections of
DNA are over-replicated. In the absence of Cyclin F, cells
critically rely on Geminin and control of CDT1 to suppress re-
replication causing genome instability and checkpoint activation.
Consistently, the absence of Cyclin F can induce cellular
senescence, a tumorigenesis barrier imposed by DNA damage
checkpoints. The overlapping mechanisms acting to prevent re-
replication ensure that lack of one regulatory pathway is not
sufﬁcient to induce re-replication. In agreement with this notion,
we found only little induction of re-replication in response to
Cyclin F depletion. Co-depletion of Cyclin F together with
Geminin, however, induces substantial re-replication, suggesting
that the degradation of CDC6 by Cyclin F cooperates with
mechanisms that suppress CDT1 activity. It was previously
reported that Geminin ablation in itself promotes re-
replication11,13,14. Here, we observe only little re-replication in
Geminin-depleted cells, which is likely due to the difference in
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our experimental setup of the co-depletion experiment, where
Cyclin F is depleted 24 h before Geminin. In any case, absence of
Cyclin F strongly promotes re-replication in Geminin knockdown
cells.
In mammalian cells, CDK phosphorylation of pre-RC
components has a direct role in blocking licensing (reviewed in
ref. 3). Speciﬁcally, CDK-phosphorylated CDT1 and ORC1 are
targeted for ubiquitin-mediated degradation by CRL1Skp2
(refs 35,36) and Orc2 chromatin binding is inhibited upon
CDK phosphorylation37,38. CDC6 is also phosphorylated by
CDKs but whether this inhibits pre-RC assembly in higher
eukaryotes is still unclear. CDK-dependent phosphorylation of
CDC6 beyond G1 can trigger nuclear export of exogenous CDC6
(refs 15–17). However, endogenous CDC6 is predominantly
nuclear throughout the cell cycle18–20 and only small fraction of
endogenous CDC6 is exported from the nucleus18–20. In this
study, we have not observed a role for CDKs in Cyclin F mediated
CDC6 inhibition. Mutations in CDC6 where all three known
CDK-phosphorylated serines were replaced with either alanine
(AAA) to mimic the unphosphorylated state or aspartic acid
(DDD) to mimic the phosphorylated state did not impact the
Cyclin F-CDC6 pathway. However, we cannot exclude that novel
CDK sites or additional post-translational modiﬁcations in CDC6
impact the Cyclin F-CDC6 pathway. In addition, it is possible
that the interaction between CDC6 and Cyclin F counteracts the
ability of other cyclins, such as Cyclin A or Cyclin B, to interact
with CDC6 through its Cy-motif. The functional and regulatory
roles of these potentially competitive interactions with CDC6 is
an interesting topic for futures studies. Moreover, our data
support a role for neddylation in CDC6 turnover39, which
supports a function of the cullin E3 ligase SCFCyclin F in
regulating CDC6 stability. Cullin E3 ligases such as SCFCyclin F
can be inhibited by MLN4924 (ref. 40), an inhibitor of cullin
neddylation and a potent antiproliferative agent that has
completed phase I trials (http://www.clinicaltrials.gov). We
found that inhibition of cullin neddylation by MLN4924
stabilized CDC6 late in the cell cycle similar to Cyclin F
depletion. MLN4924 treatment of cells induces massive
re-replication11,41, which was reported to be mediated through
inhibition of CDT1 degradation41. Our new ﬁndings suggest that
disruption of the degradation of CDC6 contributes to MLN4924
effectiveness.
Cyclin F is emerging as a new factor controlling several key cell
cycle processes late in the cell cycle including deoxyribonucleotide
triphosphate production, centrosome duplication, spindle
formation and DNA damage checkpoint maintenance through
NUSAP1, RRM2, CP110 and B-Myb23–26. In all cases, Cyclin F
operates to maintain homeostasis through the hydrophobic patch
in its Cyclin domain. This study adds an important new biological
process to the repertoire of Cyclin F actions operating by the
hydrophobic patch-dependent degradation of CDC6 to safeguard
that chromosomal DNA is precisely duplicated.
Methods
Cell culture and cell cycle synchronization and chemicals. U2OS, TIG-3-
hTERT and HEK-293T cells were obtained from American Type Culture Collec-
tion and maintained in DMEM containing 10% fetal bovine serum. Stable cell lines
expressing CDC6-V5 constructs were obtained by transducing U2OS and
TIG-3-hTERT cells, respectively, with pLenti6/UbC/CDC6-V5 constructs and
selecting transduced cells with 5 mgml 1 Blasticidin. U2OS cell lines expressing
Flag-HA-tagged Cyclin F were described previously26. For synchronization at G1/S,
U2OS cells were cultured in the presence of 2mM thymidine (Sigma) for 20 h,
washed three times with PBS and cultured in fresh medium without thymidine for
10 h. After another 17 h in thymidine, cells were washed three times with PBS and
cultured in fresh medium. To trap cells in prometaphase, U2OS cells were cultured
in the presence of nocodazole (40 ngml 1) for 5 h, before mitotic cells were
obtained by mitotic shake-off. The following additional drugs were used: 10 mM
MG132 (Sigma) and 25mgml 1 CHX (Sigma).
Plasmids and siRNA. pCMVHA-CDC6, pCMVHA-CDC6 dl 93–100,
pCMVhCDC6 AAA and pCMVhCDC6 DDD plasmids15 encoding N-terminal
HA-tagged human WT and mutant CDC6 were gifts from Dr Kristian Helin. To
create pLenti6/UbC/CDC6-V5 constructs, sequences encoding for WT and mutant
CDC6 were ampliﬁed by PCR and cloned into pLenti6/UbC/V5-DEST (Invitrogen)
according to the manufacturer’s instructions. To create truncated CDC6 expression
constructs, sequences encoding for WT and mutant CDC6 were ampliﬁed by PCR
and cloned into a pCR8/GW/TOPO vector (Invitrogen). The following primers
were used: CDC6: 50-ATGCCTCAAACCCGATCC-30 , 1086 CDC6: 50-TTATAC
CTGATTAAGTCGATCTTGCAA-30 . The entry vectors were used to generate
pGEX-6P-1 expression vector using the Gateway LR Clonase II enzyme mix
(Invitrogen) according to the manufacturer’s protocol.
HEK-293T cells were transfected with plasmid DNA using the calcium
phosphate method, as described26. U2OS were transfected with plasmid DNA
using FuGENE 6 (Promega) according to the manufacturer’s instruction.
siRNA transfections were performed with 50 nM siRNA duplexes using
Lipofectamine RNAiMAX (Invitrogen), according to the manufacturer’s
instructions. The siRNA sequences used for knockdown are (50-30): Cyclin F #1
(GGAGGACAGAUGUGUCAGA), Cyclin F #2 (GCGCAGCUGUCUUUAG
CCA), Cyclin F #3 (UAGCCUACCUCUACAAUGA), Geminin (AACUUCCAG
CCCUGGGGUUAU), and p53 (GCAGUCAGAUCCUAGCGUC).
Flow cytometry. To prepare cells for ﬂow cytometry, cells were ﬁxed in 70%
ethanol. The cells were stained with Anti-phospho-Ser/Thr-Pro MPM-2 Antibody
(1:200, Millipore) for 1 h followed by 1 h incubation with Alexa Fluor-488
anti-mouse (1:1,000) secondary antibodies. DNA was stained with 0.1mgml 1
propidium iodide containing RNase (20 mgml 1) for 30min at 37 C. For EdU
labelling, cells were incubated with 10 mM EdU for 1 h before harvest. Click-it
reaction was performed according to the manufacturer’s description (Invitrogen).
Flow cytometry was performed on a FACS Calibur (BD Biosciences) using
CellQuest Pro software (Becton Dickinson).
Immunoblotting and antibodies. Cells were lysed on ice in cold EBC-buffer
(150mM NaCl; 50mM Tris, pH 7.4; 1mM EDTA; 0.5% NP-40/Igepal) containing
protease inhibitors (1% aprotinin, 5 mgml 1 leupeptin, 1mM phenylmethyl
sulphonyl ﬂuoride (PMSF)), phosphatase inhibitors (50mM NaF; b-glyceropho-
sphate; 0.5 mM Calyculin A) and 1mM dithiothreitol (DTT). The lysates were
sonicated using a digital soniﬁer (102C CE Converter; Branson). Proteins were
separated by SDS–PAGE and transferred to a nitrocellulose membrane. Blocking
and blotting with primary antibodies were performed in PBS-T supplemented with
5% skimmed milk powder. Proteins were visualized on ﬁlms using secondary
horseradish peroxidase-conjugated antibodies (1:10,000; Vector Laboratories) and
enhanced chemiluminescence reagent (ECL) (GE Healthcare). Films were
developed using an X-ray machine (Valsoe; Ferrania Technologies). The following
commercial rabbit antibodies were used in this study: Cyclin F (sc-952, SCBT,
1/4,000 dilution), phospho-CHK2-T68 (no. 2661, Cell Signaling, 1/1,000 dilution),
Geminin (A300–935A, Bethyl Labs, 1/500 dilution) and p53-S15 (no. 9284, Cell
Signaling, 1/1,000 dilution), Phospho-RPA32 S4/S8 (A300-245A, Bethyl Labs,
1/1,000 dilution), Phospho-Chk1 S317 (no. 2344, Cell Signaling, 1/1,500 dilution).
The following commercial mouse antibodies were used in this study: Actin
(mAB1501, Chemicon Int,, 1/20,000 dilution), V5 (NB100–62264, Novus, 1/500
dilution), Vinculin (V9131, Sigma, 1/100,000 dilution), Flag (F3165, Sigma, 1/5,000
dilution), HA (MMS101P, Covance, ½,000 dilution), Anti-phospho-Ser/Thr-Pro
MPM-2 Antibody (05–368, Milipore, 1/1,000 dilution), CHK2 (DCS-270, SCBT,
1/1,000 dilution) and p53 (DO-1, supernatant, 1/100 dilution). Mouse antibodies
raised against CDC6 were described previously15 and used in a dilution of 1:5.
Supplementary Fig. 7 contains uncropped scans of the immunoblots.
Immunoﬂuorescence microscopy. For Cyclin F and V5 co-staining, cells grown
on coverslips were washed with PBS, ﬁxed with formaldehyde 4% for 10min,
permeabilized with PBS containing 0.3% Triton X-100 for 10min and blocked for
1 h in PBS containing 0.1% Triton X-100, 3% BSA before incubation with primary
antibodies Cyclin F (sc-952, SCBT, 1/500 dilution), V5 (NB100–62264, Novus,
1/500 dilution), Phospho-RPA32 S4/S8 (A300-245A, Bethyl Labs, 1/1,000 dilution).
For proliferating-cell nuclear antigen (PCNA) and H3S10ph co-staining, cells
grown on coverslips were washed with PBS, then extracted for 1min in cold
pre-extraction buffer (0.5% Triton X-100, 20mM HEPES, pH 7.5, 300mM sucrose,
50mM NaCl and 3mM MgCl2), washed with PBS and ﬁxed for 15min in
methanol at  20 C. After additional washing in PBS cell were incubated with
PCNA (Santa Cruz #SC-56, 1/1,000 dilution) and H3S10ph (Millipore, 06–570,
1/1,000 dilution) antibodies. Secondary antibodies were from donkey and
conjugated with Alexa Fluor ﬂuorochromes (Invitrogen, 1/1,000 dilution). EdU was
detected using Click-IT Alexa Fluor 647 azide (Invitrogen) and Click-IT cell
reaction buffer kit (Invitrogen #C10269). Images were acquired using an Axiovert
200M confocal microscope equipped with an LSM510 laser module (Zeiss).
Immunoprecipitations. Extracts for immunoprecipitation were prepared using
immunoprecipitation buffer (50mM HEPES, pH 7.5, 150mM NaCl, 1mM EDTA,
2.5mM EGTA, 10% glycerol, 0.1% Tween) with protease inhibitors (1% aprotinin,
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5 mgml 1 leupeptin, 1mM PMSF), phosphatase inhibitors (50mM NaF;
b-glycerophosphate; 0.5 mM Calyculin A) and 1mM DTT. Endogenous immuni-
precipitation was performed with Cyclin F antibody coupled to protein A beads
and immunoprecipitation of ectopically expressed FLAG and HA proteins was
performed with FLAG beads (Sigma, A2220) and HA beads (Sigma, A2095),
respectively. Beads were washed in immunoprecipitation buffer and incubated
with the lysate for 2 h at 4 C on a rotator. The beads were washed ﬁve times in
immunoprecipitation buffer followed by elution of bound proteins.
Puriﬁcation of recombinant proteins and binding assays. GST, WT and
dl93–100 mutant GST-CDC6 fragments (amino acids 1–362) were expressed in
Escherichia coli Rosetta (DE3) cells. Protein expression was induced with 0.2mM
IPTG for 4 h at 25 C. Cells were lysed by sonication in lysis buffer (20mM Tris,
pH 8, 200mM NaCl, 0.5% NP40) with protease inhibitors (1% aprotinin,
5 mgml 1 leupeptin, 1mM PMSF). Lysed cells were spun at 21,000g for 30min
and GST, WT and dl93–100 mutant GST-CDC6 (amino acids 1–362) were bound
to glutathione-sepharose beads (Amersham, 17-0756-01) for 1 h at 4 C. Beads
were washed four times and resuspended in 500 ml lysis buffer. In vitro translated
WT and MR/AA mutant Cyclin F, respectively, were allowed to bind for 2 h at
20 C. After binding, the beads were washed four times in lysis buffer with protease
inhibitors, and samples were eluted in 40 ml SDS sample buffer, separated on a
SDS–polyacrylamide gel and analysed by Coomassie staining and autoradiography.
In vitro transcription and translation. WT and MR/AA mutant Cyclin F were
obtained by in vitro transcription and translation with the TNT-coupled reticu-
locyte lysate system (Promega, L1170) in the presence of L-[35S]methionine-
cysteine following the instructions of the manufacturer.
Pulsed-ﬁeld gel electrophoresis. For directly assessing cellular DNA breaks, 106
cells were collected after indicated treatment and casted into agarose inserts (plugs)
before incubation in proteinase K buffer (0.5M EDTA; 1% N-laurylsarcosyl;
1mgml 1 proteinase K) at 50 C for 24 h. Plugs were washed four times in TE
buffer (10mM TRIS; 50mM EDTA) and loaded onto a 1% agarose gel (pulsed-ﬁeld
grade, Bio-Rad) and separated by pulse ﬁeld gel electrophoresis (PFGE) apparatus
for 20 h at 120 angle, 60–240 s switch time, 4V cm 1 (CHEF DR III, Bio-Rad).
In vitro ubiquitylation assay. Brieﬂy, FLAG-tagged WT Cyclin F or FLAG-tagged
Cyclin F(LP/AA) were transfected into HEK-293T cells. Anti-Flag M2 agarose
beads were used to immunoprecipitate the SCFCyclin F complex. The beads were
washed four times in lysis buffer and twice in ubiquitylation reaction buffer
(10mM Tris-HCl, pH 7.5, 100mM NaCl, 5mM MgCl2 and 1mM DTT). Beads
were then used for an in vitro ubiquitylation assays, which were performed in a
volume of 30ml, containing 2mM ATP, 0.5 mM E1 (Boston Biochem), 10 ng ml 1
Ubch3, 10 ng ml 1 Ubch5c, 1 mM ubiquitin aldehyde and 3 mg ml 1 ubiquitin
(Sigma)25. The reactions were incubated at 30 C for 2 h and analysed by
immunoblotting with antibodies to CDC6.
Senescence staining. b-Galactosidase staining was performed with the
Senescence b-Galactosidase Staining Kit (Cell Signaling, #9860) according to
the manufacturer’s instructions.
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